Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62027 | 0.94 | PLAU (0.52) | CA1CA2PLAUNOS1MAPT | |
| SCHEMBL4266913 | 0.89 | ALDH1A1 (0.51) | PLAUNOS1MAPTLMNATSHR | |
| SCHEMBL4266917 | 0.89 | ALDH1A1 (0.51) | PLAUNOS1MAPTLMNATSHR | |
| SCHEMBL21630438 | 0.89 | PLAU (0.47) | PLAUNOS1MAPTLMNATSHR | |
| SCHEMBL8163344 | 0.87 | ALDH1A1 (0.54) | PLAUNOS1MAPTLMNATSHR | |
| SCHEMBL11593921 | 0.84 | HSPB1 (0.56) | CA1CA2CA9PLAUNOS1 | |
| SCHEMBL9357905 | 0.84 | APP (0.55) | CA12CA1CA2CA9PLAU | |
| SCHEMBL11221931 | 0.84 | HPGD (0.58) | CA1CA2PLAUNOS1MAPT | |
| SCHEMBL9557695 | 0.84 | MAPT (0.51) | PLAUNOS1MAPTLMNATSHR | |
| SCHEMBL9357909 | 0.84 | APP (0.55) | CA12CA1CA2CA9PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0621962-A1 | FUNCTIONALIZED MEROCYANINE DYES AND POLYMERS INCORPORATING SUCH DYES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5256784-A | Merocyanine dyes | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| WO-1993015596-A2 | FUNCTIONALIZED MEROCYANINE DYES AND POLYMERS INCORPORATING SUCH DYES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | CA12 1927/4885CA1 2142/4885CA2 2844/4885 |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | NR1H2, NR1H3, SREBF1 | CA12 4879/4885CA1 4876/4885CA2 4668/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | CA12 1927/4885CA1 2142/4885CA2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.